The relationship between methionine synthase rs1805087 polymorphism and hematological cancers risk.

Abstract

Background: The relationship between hematological cancer susceptibility and methionine synthase MTR A2756G (rs1805087) polymorphism is inconclusive based on data from past studies. Hence, this updated meta-analysis was conducted to investigate the relationship between methionine synthase reductase (MTR) rs1805087 polymorphism and hematological cancers. Method: We searched EMBASE, Google Scholar, Ovid and PubMed databases for possible relevant articles up to December 31, 2019. Results: The overall pooled outcome of our analysis showed lack of association between the risk of hematological malignancies and MTR A2756G polymorphism under the allele model (G vs A: odds ratio = 1.001, 95% CI: 0.944-1.061; p = 0.983), recessive model (GG vs GA + AA: odds ratio = 1.050, 95% CI: 0.942-1.170; p = 0.382). Conclusion: The findings in this study demonstrate a lack of relationship between hematological cancers and MTR A2756G.

• Authors: Yanliang Bai, Emmanuel Kwateng Drokow, Hafiz Abdul Waqas Ahmed, Juanjuan Song, Gloria Selorm Akpabla, Maame Awoyoe Kumah, Emmanuel Bamfo Agyekum, Enyonam Adjoa Neku, Kai Sun
• Journal: Future oncology (London, England) (Future Oncol) Vol. 16 Issue 28 Pg. 2219-2233 (Oct 2020) ISSN: 1744-8301 [Electronic] England
• PMID: 32722923 (Publication Type: Journal Article, Meta-Analysis)

Chemical References

• 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
• MTR protein, human

Topics

• 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase (genetics)
• Alleles
• Case-Control Studies
• Genetic Association Studies
• Genetic Predisposition to Disease
• Genotype
• Hematologic Neoplasms (diagnosis, genetics)
• Humans
• Odds Ratio
• Polymorphism, Single Nucleotide
• Publication Bias
• Risk Assessment
• Risk Factors